ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Targeting Genes With 'Zinc Fingers'

by Stuart A. Borman
December 20, 2010 | APPEARED IN VOLUME 88, ISSUE 51

CUTTING TOOL
[+]Enlarge
Credit: © 2010 Sigma-Aldrich
Sigma-Aldrich markets zinc finger nucleases (ZFNs) designed to edit DNA. ZFNs combine zinc fingers (gray, zinc atoms are spheres) that recognize a three-base-pair DNA sequence with a domain (triangle) from the restriction endonuclease FokI, which cleaves DNA (in the red area). The break is then repaired to modify the sequence or create a gene knockout. A, C, G, and T are DNA bases, and C and N are protein termini.
8851cover2_zinc.jpg
Credit: © 2010 Sigma-Aldrich
Sigma-Aldrich markets zinc finger nucleases (ZFNs) designed to edit DNA. ZFNs combine zinc fingers (gray, zinc atoms are spheres) that recognize a three-base-pair DNA sequence with a domain (triangle) from the restriction endonuclease FokI, which cleaves DNA (in the red area). The break is then repaired to modify the sequence or create a gene knockout. A, C, G, and T are DNA bases, and C and N are protein termini.

COVER STORY

Targeting Genes With 'Zinc Fingers'

In 2000, Yen Choo, Chemistry Nobel Laureate Aaron Klug, and coworkers at the MRC Laboratory of Molecular Biology, in Cambridge, England, developed "zinc fingers"—zinc-coordinated protein-based binding agents—that regulate gene transcription by targeting just about any 18-base-pair DNA sequence. The team announced that the technology was being developed by the London-based start-up Gendaq.

GENOME EDITING
[+]Enlarge
Credit: © 2010 Sigma-Aldrich
This animation reveals how CompoZr zinc finger technology can be used to edit genomes in cell lines.
8851cover2vid1.jpg
Credit: © 2010 Sigma-Aldrich
This animation reveals how CompoZr zinc finger technology can be used to edit genomes in cell lines.
ZINC-FINGER TALK
[+]Enlarge
Credit: © 2010 Web of Stories
Aaron Klug discusses Yen Choo, Gendaq, and Sangamo BioSciences' buyout of Gendaq.
8851cover2vid2.jpg
Credit: © 2010 Web of Stories
Aaron Klug discusses Yen Choo, Gendaq, and Sangamo BioSciences' buyout of Gendaq.

Gendaq "did pretty well for itself," says Choo, who is now chief executive officer of the London-based stem cell biotech firm Plasticell. Gendaq made good scientific progress and was sold in 2001 to Sangamo BioSciences for $30 million, Choo notes. Sangamo later licensed research applications of customizable zinc finger technology to Sigma-Aldrich, which now markets it commercially under the trade name CompoZr (C&EN, April 5, page 20).

Researchers now use zinc finger technology to make a variety of genetic modifications—inserting a piece of DNA in a defined place in the genome, creating point mutations in a specific gene, or correcting a gene's sequence defect. "You can knock stuff in, knock stuff out, or change it," Choo says. "Zinc fingers act very specifically to target the particular sequence you're interested in—by virtue of the inherent specificity of zinc fingers and, in particular, of the engineering system that we developed."

Zinc fingers aren't yet being used in any approved therapies, but Choo notes that the opportunities are there for it to happen soon. For example, Sangamo is currently using zinc finger nucleases in three Phase I clinical trials to knock out the gene coding for HIV-entry receptors on patient immune-system stem cells. The idea is to reintroduce the modified cells to the patient in hopes that the cells will form a new population of HIV-resistant immune cells. Sangamo has also completed four Phase II clinical trials of a zinc finger therapeutic in diabetic neuropathy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment